Comitas e-health and the Andalusian company Keyzell have formalized an alliance for the development of an innovative telemedicine solution for the early diagnosis and treatment of breast and lung cancer . The new tele-diagnosis solution, based on the use of Artificial Intelligence (AI) in the analysis of breast and lung X-rays, will reduce the impact of these diseases among the population at risk, especially in the most geographically isolated areas.
The agreement is part of the Strategic Growth Plan of Comitas, whose objective is to bring Diagnostic Telemedicine to all areas of society, improving health care and the experience of patients.
For its part, Keyzell is a biotech startup based in Seville that has developed the world’s first oncology precision medicine system, based on AI, which selects “the best personalized treatment for each type of patient.” Specifically, Keyzell has developed an AI system for the diagnosis of cancer by imaging, which allows to improve the accuracy of the diagnosis through an X-ray or a positron emission tomography known as PET and DICOM standards. The device has been trained with a total of 108,948 chest x-ray images corresponding to 32,717 patients. The processing time per radiograph is less than one minute and allows the generation of work queues simultaneously by multiple users.
This Precision Medicine tool is now capable of helping radiologists detect a tumor mass in a patient with 92% accuracy and offer the diagnosis to the radiologist in less than a minute. The prototype has been trained for lung cancer and breast cancer and “validated by an ethical committee.”
Comitas e-health Diagnostic Telemedicine solutions allow real-time monitoring of vital signs and control of temperature, blood oxygen level, blood pressure and heart rate. In addition, they have an electrocardiograph to measure the activity of the heart, an ultrasound scanner and other devices to study other parts of the body such as the throat, skin, eyes, ears and perform ultrasound scans. To these are added “a fleet of mobile diagnostic imaging units, which allow X-rays and ultrasounds to be performed anywhere, without the need to go to a medical center,” they explain.
“The agreement with Keyzell -says Aquilino Antuña, CEO of Comitas- will offer a precision telediagnosis and the selection of the best therapies and treatments, personalized for each patient, improving their effectiveness and helping them to better overcome the disease”. For José de Corral, CEO of Keyzell , the company’s objective is for the Diagnostic Imaging tool “to be a benchmark against cancer in the field of precision medicine, reversing the mortality figures for this disease”, adding that the agreement with Comitas will allow them to “broaden the scope of application and take it to the patient’s home anywhere in the world”.
Comitas e-health, is a pioneer company in the provision of telemedicine services, with more than 25 years in the sector. For its part, KeyZell -a company founded in 2020-, specializes in offering oncological solutions based on precision medicine that improve the quality of life of patients.
